Tetraphase Completes Enrollment of IGNITE3 Phase 3 Clinical Trial

Tetraphase Pharmaceuticals (NASDAQ:TTPH) announced the completion of enrollment in IGNITE3, its ongoing phase 3 clinical trial.
As quoted in the press release:

The Company expects to report top-line data from this trial in the first quarter of 2018.
“We have now completed enrollment of approximately 1,200 patients in IGNITE3, well ahead of schedule, and we expect top-line data from IGNITE3 to be available during the first quarter of 2018,” said Guy Macdonald, President and CEO of Tetraphase.  “In parallel, we are working to prepare a New Drug Application (NDA) for twice-daily IV eravacycline in complicated intra-abdominal infections, which will be comprised of data from the successfully completed phase 3 IGNITE1 and IGNITE4 clinical trials.

Click here to read the full press release.

Source: globenewswire.com